/compare — side-by-sideLOADING
Valuation, growth, margins and forensic scores side-by-side — computed from each company's own SEC filings and last EOD close. No estimates, no fluff.
| Metric | ADILADIAL PHARMACEUTICAL |
|---|---|
| Last close | $5.05close 2026-10-28 |
| Change % | +36.12%close 2026-10-28 |
| Market cap | $13Mclose 2026-10-28 |
| P/E | — |
| Revenue | — |
| Rev growth (YoY) | — |
| Net income | $-7978000000000⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldNetIncomeLoss As ofFY ending 2025-12-31 FilingDEF 14A · 0001213900-26-093019 · filed 2026-08-24 Open the filing on EDGAR →Open the XBRL payload →CiteADIAL PHARMACEUTICALS, INC. (ADIL), us-gaap:NetIncomeLoss: -7,978,000,000,000 USD, fiscal year ended 2025-12-31. Form DEF 14A, accession 0001213900-26-093019, filed 2026-08-24. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0001513525/us-gaap/NetIncomeLoss.json |
| Net margin | — |
| EPS (diluted) | $-11.93⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldEarningsPerShareDiluted As ofFY ending 2025-12-31 Filing10-K · 0001213900-26-024175 · filed 2026-03-05 Open the filing on EDGAR →Open the XBRL payload →CiteADIAL PHARMACEUTICALS, INC. (ADIL), us-gaap:EarningsPerShareDiluted: -11.93 USD per share, fiscal year ended 2025-12-31. Form 10-K, accession 0001213900-26-024175, filed 2026-03-05. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0001513525/us-gaap/EarningsPerShareDiluted.json |
| Piotroski F-ScoreUNVALIDATED | — |
| Altman Z-ScoreUNVALIDATED | — |
| Beneish M-ScoreUNVALIDATED | — |
| Next earnings | 11-08 → 11-18 |
Fundamentals from XBRL company facts (as filed); market cap & P/E use last EOD close. Each cell names its period. A ratio row reads not comparable when the companies’ periods differ by more than six weeks or mix a fiscal year with a trailing twelve months, and a figure more than a year older than the company’s newest period is marked older period. No row ranks the companies. Educational only, not investment advice.